Top Stories: Page 46

How Much Did an Ounce of Cannabis Flower Cost in 2023?

While average prices per ounce hit rock bottom in some states this past year, prices in other markets remain relatively high despite comparable maturities.

How the Nation’s 6 Newest Adult-Use Cannabis Markets Performed in 2023 (With Projections for 2024)

New York took a backseat to Missouri and Maryland, while Connecticut, Rhode Island and Vermont got their adult-use feet wet.

CBT’s Most Popular Articles: December

Here are Cannabis Business Times’ most-viewed stories this month.

5 Cannabis Policy Reform Efforts to Watch in 2024

From the SAFER Banking Act to state-level reform, Akerman’s Jonathan Robbins outlines the legislation and potential policy changes on the horizon for the industry.

The Top 10 Best-Selling Flower Strains in California in 2023

You'd better believe it: Blue Dream takes the cake this year.

Cannabis Business Times’ Top 10 Videos and Podcasts of 2023

Here are the videos you watched the most this year and the podcasts you listened to the most this year.

Cannabis Industry to 2023: 'Don’t Let the Door Hit You in the …'

In this dynamic roundup, 10 executives at plant-touching businesses and policy experts share their candid thoughts as they look back on 2023 and what they’re anticipating for 2024, including a healthy dose of optimism.

13 Cannabis Industry Takeaways From 2023—and Future Predictions for 2024 and Beyond

Cannabis market research firm BDSA details insights behind its forecasts and which industry trends were most surprising this year.

Cannabis Dispensaries Top Target for Labor Unions as More States Legalize

With the National Labor Relations Board adopting standards making it easier to organize, unions have recognized that now is the time to attack.

Editors’ Picks: The CBT Team Selects Their Favorite Conference Sessions From 2023

We're looking back to some of our favorite sessions at Cannabis Business Times' conference in August 2023.

Cannabis Business Times’ Top 10 Articles of 2023

A roundup of our most-read stories from the past year.

Former US Attorneys Urge Federal Officials to Reject Cannabis Rescheduling Recommendation

Eric Berlin, partner at Dentons, shares insight into some of the arguments the 29 former attorneys make against removing cannabis from Schedule I of the Controlled Substances Act.

Previous Page

Page 46 of 253

Next Page